CA3238932A1 - Composition pharmaceutique comprenant du salbutamol - Google Patents

Composition pharmaceutique comprenant du salbutamol Download PDF

Info

Publication number
CA3238932A1
CA3238932A1 CA3238932A CA3238932A CA3238932A1 CA 3238932 A1 CA3238932 A1 CA 3238932A1 CA 3238932 A CA3238932 A CA 3238932A CA 3238932 A CA3238932 A CA 3238932A CA 3238932 A1 CA3238932 A1 CA 3238932A1
Authority
CA
Canada
Prior art keywords
mass
pharmaceutical composition
pharmaceutical
salbutamol
ethanol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3238932A
Other languages
English (en)
French (fr)
Inventor
Isabelle PEYRON
Irene ROSSI
Segolene Sarrailh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aptar France SAS
Original Assignee
Aptar France SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aptar France SAS filed Critical Aptar France SAS
Publication of CA3238932A1 publication Critical patent/CA3238932A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CA3238932A 2021-12-20 2022-12-19 Composition pharmaceutique comprenant du salbutamol Pending CA3238932A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FRFR2113999 2021-12-20
FR2113999A FR3130554B1 (fr) 2021-12-20 2021-12-20 Composition pharmaceutique comprenant du salbutamol
PCT/FR2022/052421 WO2023118717A1 (fr) 2021-12-20 2022-12-19 Composition pharmaceutique comprenant du salbutamol

Publications (1)

Publication Number Publication Date
CA3238932A1 true CA3238932A1 (fr) 2023-06-29

Family

ID=80595325

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3238932A Pending CA3238932A1 (fr) 2021-12-20 2022-12-19 Composition pharmaceutique comprenant du salbutamol

Country Status (9)

Country Link
US (1) US20250041244A1 (enExample)
EP (1) EP4452227B1 (enExample)
JP (1) JP2024546201A (enExample)
CN (1) CN118510492A (enExample)
AU (1) AU2022420913A1 (enExample)
CA (1) CA3238932A1 (enExample)
FR (1) FR3130554B1 (enExample)
MX (1) MX2024006942A (enExample)
WO (1) WO2023118717A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250281404A1 (en) * 2024-03-07 2025-09-11 Recipharm Laboratories, Inc. Composition for use in pressurised dispensing container

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007020204A2 (en) * 2005-08-12 2007-02-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Hfc solution formulations for inhalation containing salbutamol hydrochloride or salbutamol citrate
GB201117621D0 (en) 2011-10-12 2011-11-23 Mexichem Amanco Holding Sa Compositions
GB201117619D0 (en) 2011-10-12 2011-11-23 Mexichem Amanco Holding Sa Compositions
GB201306984D0 (en) 2013-04-17 2013-05-29 Mexichem Amanco Holding Sa Composition
GB2573297A (en) * 2018-04-30 2019-11-06 Mexichem Fluor Sa De Cv Pharmaceutical composition

Also Published As

Publication number Publication date
EP4452227C0 (fr) 2025-11-26
MX2024006942A (es) 2024-09-10
EP4452227B1 (fr) 2025-11-26
JP2024546201A (ja) 2024-12-18
US20250041244A1 (en) 2025-02-06
CN118510492A (zh) 2024-08-16
AU2022420913A1 (en) 2024-05-23
FR3130554B1 (fr) 2024-10-18
FR3130554A1 (fr) 2023-06-23
EP4452227A1 (fr) 2024-10-30
WO2023118717A1 (fr) 2023-06-29

Similar Documents

Publication Publication Date Title
TWI546094B (zh) 用於經由呼吸道輸送活性劑的組成物以及相關方法與系統
CN1177582C (zh) 含HFA227和HFA134a的药物气雾剂组合物
HU228487B1 (en) Pharmaceutical aerosol composition
JP2009534387A5 (enExample)
FR2820322A1 (fr) Formulation pharmaceutique de propionate de fluticasone
EP2040670A1 (en) Stable aerosol pharmaceutical formulations
WO2014190204A1 (en) Compositions, methods & systems for respiratory delivery of three or more active agents
CN102905694B (zh) 吸入溶液
JP2010508256A (ja) 加圧型用量計量吸引器による送達のための処方剤
EP4452227B1 (fr) Composition pharmaceutique comprenant du salbutamol
JP2004515454A (ja) 気管支肺疾患の治療のためのグルココルチコイド薬物を含有する製剤
RU2582218C2 (ru) Способ получения дозирующего распыляющего ингалятора для лечения респираторного заболевания
EP4554568B1 (fr) Composition pharmaceutique comprenant du salbutamol
WO2021033081A1 (en) Stable aerosol composition for inhalation comprising glycopyrronium, formoterol and corticosteroid
EP4452230A1 (en) Compositions, methods and systems for aerosol drug delivery
CN105106200A (zh) 用于呼吸递送两种或多种活性剂的组合物、方法和系统
EP2429297A1 (en) Method of administering dose-sparing amounts of formoterol fumarate-budesonide combination particles by inhalation
JP2007528889A (ja) 吸入製剤
HK1228797B (en) Compositions for respiratory delivery of active agents and associated methods and systems

Legal Events

Date Code Title Description
P22 Classification modified

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED

Effective date: 20241115

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241211

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241211

R00 Party data change recorded

Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R00-R116 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPOINTMENT OF AGENT REQUEST

Effective date: 20251001

Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R00-R119 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REVOCATION OF AGENT REQUEST

Effective date: 20251001

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251001

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251217

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251217

R17 Change to representative recorded

Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R17-R121 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REVOCATION OF AGENT REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260324

Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R17-R117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPOINTMENT OF AGENT REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260324

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260324